Hyalase

Hyalase is a prescription‑only solution for injection that contains the enzyme hyaluronidase. It is supplied in the European market and is administered by intramuscular or subcutaneous injection. Hyaluronidase acts as an adjunctive therapy, facilitating the dispersion and absorption of co‑administered agents by breaking down hyaluronic acid in the extracellular matrix. The product is used under the supervision of a qualified healthcare professional in a clinical setting.

Hyalase is employed as an adjunctive agent to improve the delivery and effectiveness of other injectable therapies. Its enzymatic activity enhances tissue permeability, allowing more uniform distribution of co‑administered drugs.

- Enhancement of subcutaneous fluid administration, such as contrast media or irrigation solutions. - Improvement of local anesthetic spread for regional blocks. - Facilitation of absorption of co‑administered antibiotics, chemotherapeutic agents, or other injectables. - Treatment of extravasation injuries caused by vesicant chemotherapy agents. - Support of subcutaneous infusion devices by reducing tissue resistance.

Adverse reactions to Hyalase are generally related to its enzymatic activity and the injection procedure. Reported events range from mild, transient symptoms to rare serious complications.

Common: - Localized pain, tenderness, or burning at the injection site. - Redness, swelling, or mild erythema around the administration area. - Transient itching or mild rash. - Temporary increase in tissue permeability leading to mild edema.

Serious: - Allergic reactions including urticaria, angioedema, or anaphylaxis. - Severe hypersensitivity with respiratory distress or hypotension. - Tissue necrosis or ulceration at the injection site. - Systemic effects such as fever or chills.

When using Hyalase, clinicians should evaluate patient history and follow specific safety measures to minimize risks associated with enzymatic activity and injection.

- Confirm absence of known hypersensitivity to hyaluronidase or any component of the formulation. - Assess for active infections or open wounds at the intended injection site. - Use the lowest effective dose and limit the volume of injection to reduce tissue irritation. - Monitor patients for immediate allergic reactions during and after administration. - Avoid use in pregnant or breastfeeding women unless the potential benefit justifies the potential risk. - Exercise caution in patients with cardiovascular disease or uncontrolled asthma.

Hyalase may interact with other agents that influence immune response or tissue integrity. Awareness of potential interactions helps ensure safe co‑administration.

Avoid: - Concurrent use with other hyaluronidase‑containing products, which may increase enzymatic activity excessively. - Administration together with vesicant chemotherapeutic agents without appropriate extravasation precautions.

Use with caution: - Co‑administration of large volumes of local anesthetics, as increased spread may enhance systemic absorption. - Simultaneous injection of biologic agents that could be degraded by hyaluronidase. - Use with anticoagulants, monitoring for prolonged bleeding at the injection site.